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Abstract The paracaspase MALT1 has a central role in
the activation of lymphocytes and other immune cells
including myeloid cells, mast cells and NK cells. MALT1
activity is required not only for the immune response, but
also for the development of natural Treg cells that keep the
immune response in check. Exaggerated MALT1 activity
has been associated with the development of lymphoid
malignancies, and recently developed MALT1 inhibitors
show promising anti-tumor effects in xenograft models of
diffuse large B cell lymphoma. In this review, we provide an
overview of the present understanding of MALT1’s func-
tion, and discuss possibilities for its therapeutic targeting
based on recently developed inhibitors and animal models.
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Abbreviations
ABC Activated B cell
BCL10 B-cell lymphoma-10
CARD Caspase recruitment domain
CARMA1 CARD-containing membrane-associated
guanylate kinase-1
DLBCL Diffuse large B-cell lymphoma
EAE Experimental autoimmune encephalomyelitis
GCB Germinal center B cell
MALT1 Mucosa-associated lymphoid tissue protein-1
MCL Mantle cell lymphoma
Introduction
The paracaspase MALT1 plays an essential role in the
activation of immune cells by specific subtypes of immune
receptors, which induce a common signaling pathway
leading to the activation of the transcription factor NF-jB.
NF-jB target genes include cytokines and anti-apoptotic
proteins, which together promote the activation, prolifera-
tion and survival of the activated immune cells upon
receptor triggering, and thereby allow the efficient gener-
ation of an immune response. MALT1 is also involved in
the activation of non-immune cells, in which an NF-jB
response can be induced by specific G protein-coupled
receptors (GPCRs) or the epidermal growth factor (EGF)
receptor (Fig. 1). In this review, we will focus mainly on
the role of MALT1 in immune cells. Readers interested in
the role of MALT1 in non-immune cells are referred to an
excellent recent review covering this topic [1].
Molecular and biological functions of MALT1
MALT1 functions downstream of immunoreceptors
with an ITAM sequence
The ligand-dependent activation of adaptive and innate
immune cells via cell surface receptors that recognize
various non-self features is an essential initiating step of
the immune response. Not all immune receptors activate
MALT1. Indeed, MALT1 specifically transmits signals
from immune receptors with a so-called ITAM (im-
munoreceptor tyrosine-based activation motif), towards the
activation of the transcription factor NF-jB (see Fig. 1 and
specific references therein). Prototype members of these
receptors are the B-cell and T-cell receptor (BCR and
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TCR), which associate with ITAM-containing CD79 or
CD3 chains and recognize antigenic proteins or processed
peptide antigens, respectively. Other types of immune cell
receptors that signal via ITAM motifs are Fc receptors,
which are expressed on myeloid and mast cells and rec-
ognize antibody-coated antigenic structures. The myeloid
receptors Dectin-1, Mincle and TREM1, contain either an
ITAM domain or associate with the ITAM-containing
FcRc chain, and activate innate immune cells upon
recognition of microbial glycoproteins [2, 3]. Finally,
activating natural killer (NK) cell receptors expressed on
NK cells, which associate with ITAM-bearing signaling
subunits such as DAP12 or CD3f, recognize cellular stress
ligands or antigenic structures presented by non-classical
MHC molecules [4]. A common consequence of the trig-
gering of ITAM-containing receptors is the NF-jB-
dependent expression of proliferation and inflammation-
promoting genes, in particular of immune-stimulating
cytokines, in the activated immune cells.
MALT1 has a central role in the immune response
Genetic studies using MALT1-deficient mice have revealed
that MALT1 plays an essential role in immunoreceptor-
induced activation events, since mice lacking functional
MALT1 are immunodeficient [5, 6]. In particular, these
mice show impaired B- and T-cell responses to immu-
nization or viral infection, impaired Fc-receptor mediated
cytokine responses of myeloid and mast cells, strongly
reduced NK cell responses and impaired innate immunity to
yeast infections [5–9]. Additionally, MALT1-deficient mice
or mice expressing a catalytically inactive form of MALT1,
have impaired development of specific B-cell subsets, such
as B1 and marginal zone B cells, and of regulatory T cells
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Fig. 1 Receptor-induced signaling via MALT1. BCL10 and MALT1
act together to activate NF-jB downstream of receptors containing
ITAMs and G protein-coupled receptors. The B- and T-cell receptor
(BCR and TCR, respectively) and natural killer (NK)-cell receptors
such as NKG2D, NK1.1, Ly49D and Ly49H, mediate signals through
CARMA1. ITAM-containing receptors expressed by myeloid and
mast cells, such as Dectins, FccRs, OSCAR, TREM-1 and Mincle
mediate signals through CARD9, while GPCRs signal through
CARMA3 for the activation of the BCL10-MALT1 module. ITAM
immunoreceptor tyrosine-based activation motif, FcRc Fc receptor
c-chain; PKC protein kinase C, IKK inhibitor of NF-jB (IjB) kinase
complex, OSCAR osteoclast associated, immunoglobulin-like recep-
tor, TREM-1 triggering receptor expressed by myeloid cells 1
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[5, 6, 10–13], most likely as a consequence of impaired
BCR and TCR signals during lymphocyte development
(Fig. 2). MALT1-dependent TCR signaling is also strictly
required for the development of effector T cells of the TH17
type [14, 15]. Recently, a small number of human patients
with defects in MALT1 expression and/or function have
been described [16–18]. A common feature of these patients
is combined immunodeficiency, characterized by severe
recurrent infections and impaired cellular and humoral
immune responses despite normal numbers of circulating
B- and T-cells. Collectively, these observations support an
essential role for MALT1 in the immune response that is
due to its essential signaling function downstream of
ITAM-containing immunoreceptors.
Immunoreceptors with ITAM motifs activate
MALT1 via PKC and CARD proteins
How do ITAM-containing immunoreceptors activate
MALT1? A common feature of these receptors is that their
ITAM motif(s) become(s) rapidly phosphorylated by Src
family kinases in response to binding of the antigenic
ligand to the receptor. This is followed by the physical
recruitment of the Syk family kinases ZAP70 or Syk to the
doubly phosphorylated ITAM motif [19]. The signal is
then relayed by Ser/Thr kinases of the PKC family, which
in turn phosphorylate the scaffold protein CARMA1
(CARD-MAGUK1, also known as CARD11) [20, 21] or
the CARMA1 homologue CARD9 [22], thereby promot-
ing the physical assembly of oligomeric CARMA1/
CARD9-BCL10-MALT1 (CBM) complexes (Fig. 1). The
stoichiometry of these complexes is not well defined;
recent findings suggest that the CBM signalosome is a
filamentous assembly in which CARMA1 nucleates for-
mation of BCL10 filaments that are decorated with
MALT1 [23]. In non-immune cells, the CARMA1
homologue CARMA3 (also known as CARD10) is
thought to play a similar role in promoting BCL10- and
MALT1-dependent NF-jB activation downstream of G
protein-coupled receptors or the EGFR [24–26]. The
CARMA1-homologue CARMA2 (also known as
CARD14) has been proposed to drive NF-jB activation in
keratinocytes of the skin [27, 28], but the upstream signals
triggering CARMA2 activation remain unknown. As a
consequence of its BCL10-dependent physical recruitment
into a CBM complex, MALT1 promotes NF-jB activation
via both its scaffold and protease functions (Fig. 3). As a
scaffold, MALT1 recruits ubiquitin ligases that promote
the activation of the IjB kinase (IKK) complex [29–33].
IKK-dependent phosphorylation targets the NF-jB inhi-
bitor, IjB, for proteasomal degradation and thereby allows
NF-jB subunits to enter the nucleus and to initiate the
transcription of NF-jB target genes [34]. The protease
activity of MALT1, on the other hand is essential for NF-
jB signal amplification and persistence, which is achieved
mainly by the cleavage of two negative regulators of the
NF-jB pathway, namely RelB and A20 [35, 36]. So far,
the relevance of MALT1 protease activity for NF-jB
activation has been formally demonstrated for receptors
depending on CARMA1 or CARD9 [10–13, 35, 37];
whether it is also relevant for CARMA2- and CARMA3-
dependent NF-jB signals remains uncertain [38].
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Recently, several new substrates of MALT1 have been
identified. These substrates control additional aspects of
leukocyte activation such as activation of AP-1 tran-
scription factors and regulation of transcript stability [39–
41]. The molecular features of the MALT1 scaffold and
protease functions and their biological relevance are fur-
ther detailed below.
The scaffold function of MALT1 is defined by its
protein binding motifs
Over the last few years, our understanding of the function
of MALT1 has considerably been improved by molecular
and biochemical analyses, which have dissected individual
functions of specific structural subdomains present in the
MALT1 protein (Fig. 4a). MALT1 contains a predicted
N-terminal death domain of unknown function, followed
by two immunoglobulin (Ig)-like domains that have been
shown to be essential for its constitutive binding to the
adaptor protein BCL10 [42, 43]. In addition, MALT1
contains a central catalytic domain that has homology with
proteases of the caspase family [42]. Shared features
include a conserved Cys and His residue required for
catalysis and a typical three-dimensional fold of the pro-
tease domain, which can dimerize [42, 44, 45] (Fig. 4b).
The protease domain is followed by a third Ig-like domain
that contains important sites for mono- and polyubiquiti-
nation, and by a C-terminal extension of unknown
structure. The capacity of MALT1 to recruit the ubiquitin
ligase TRAF6 and to thereby activate the IKK complex has
been attributed to two individual TRAF6 binding motifs
located outside the protease domain [30, 31] (Fig. 4a).
TRAF6 recruitment to MALT1 is thought to promote IKK
activation by polyubiquitination of MALT1 together with
its binding partner BCL10 and TRAF6 itself [29, 31, 46].
The resulting K63-linked polyubiquitin chains are thought
to provide docking sites for the recruitment of the kinase
TAK1 via TAB 2/3 adaptor proteins [47, 48], which allows
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Fig. 3 Overview of MALT1-dependent lymphocyte activation via its
scaffold and protease functions. Through its scaffold function,
MALT1 promotes NF-jB activation via recruitment of the ubiquitin
ligase TRAF6, the linear ubiquitin chain assembly complex LUBAC
(composed of Sharpin/HOIL/HOIP) and the Ser/Thr kinase TAK1 to
activate the IKK complex, which phosphorylates the NF-jB inhibitor
IjB to target it for proteasomal degradation. MALT1 protease activity
controls NF-jB activation, AP-1 activation, mRNA stability and
cellular adhesion by the cleavage of various substrates (see text for
details). Positions and sequences of MALT1 cleavage sites in the
individual substrates are indicated
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TAK1 to phosphorylate and thereby activate the catalytic
IKK subunit IKKb [31, 48]. MALT1 also associates with
the linear ubiquitination chain assembly complex LUBAC
(also known as the Sharpin/HOIL/HOIP complex) [32, 33],
but the consequences of this interaction for IKK activation
remain incompletely understood. It is most likely that the
linear ubiquitination of CBM- or associated components
provides docking sites for the physical recruitment of the
IKK complex through the linear ubiquitin chain-binding
UBAN motif of the IKK subunit IKKc (also known as
NEMO) [47, 49]. Collectively, these findings support the
idea that MALT1 can act as a scaffold to coordinate the
recruitment and activation of TRAF6 and the kinases
TAK1 and IKK for NF-jB activation.
The protease activity of MALT1 is required
for optimal NF-jB and AP-1 activation
Over the last years, it has become clear that MALT1 sig-
naling downstream of ITAM-containing receptors depends
not only on its scaffold function, but to a large extent on its
protease activity. A specific feature of MALT1 activation
that differentiates it from proteases of the caspase family is
the requirement of the third Ig domain (Ig3), which forms
several hydrophobic contacts with the adjacent protease
domain that are released upon substrate binding (Fig. 3a, b)
[44, 45]. This suggests a model in which the auto-in-
hibitory Ig3 domain contributes to MALT1 activation by
an inducible conformational change in this region [44, 50].
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Fig. 4 Molecular structure and function of MALT1. a MALT1
contains an N-terminal death domain (DD), followed by two
immunoglobulin-like domains (Ig), which are required for the
interaction between MALT1 and BCL10. The central caspase-like
domain, with the active site residues H415 and C464, is followed by a
third Ig domain that contains K644, a monoubiquitination site that
controls protease activity. MALT1 contains two binding motifs for
the ubiquitin ligase TRAF6 (tumor necrosis factor receptor-associated
factor 6). TRAF6 polyubiquitinates MALT1 on multiple C-terminal
lysine residues, generating K63-linked ubiquitin chains that can in
turn promote activation of the inhibitor of NF-jB kinase (IKK)
complex through recruitment of the IKK-activating kinase TAK1 via
the adaptor proteins TAB 2/3. Amino acid numbering in the
figure refers to human MALT1. b Ribbon representation of the
crystallographic structure of the MALT1 homodimer (figure repro-
duced from Yu et al., PNAS 108 (52), 21004–21009 (2011), with kind
permission) [45]. The shown crystallized fragment comprises the
paracaspase region (blue) and the adjacent C terminal Ig domain
(orange). The covalently bound MALT1 peptide inhibitor is colored
red and the subunit linker in the caspase-like fold is colored yellow.
The sequences between the caspase-like domain and the Ig domain
are disordered and represented as gray dotted lines
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Interestingly, MALT1 activity is tightly controlled by
antigen receptor-induced monoubiquitination of MALT1
on residue K644 within the Ig3 domain (Fig. 3a), and this
modification induces or stabilizes MALT1 dimerization via
the protease domain [51, 52].
With the discovery of the proteolytic activity of MALT1
and of specific MALT1 protein substrates, our under-
standing of MALT1 function has been considerably
enriched (Fig. 3c). The protease activity of MALT1 is
thought to promote NF-jB activation through the cleavage
of the deubiquitinating enzyme A20 and of the NF-jB
subunit RelB. How exactly A20 cleavage affects NF-jB
activation remains unclear. A20 can negatively regulate
IKK-dependent NF-jB activation by deubiquitination of
MALT1 [53], and A20 levels decrease shortly after T-cell
stimulation [53]. However, MALT1 activity is neither
required for A20 degradation [53] nor for IKK-dependent
IjBa phosphorylation [10–12, 36, 53], and the proportion
of inducible A20 cleavage is relatively small [35]. This
suggests that MALT1-dependent A20 cleavage may serve
to generate an A20 fragment that affects NF-jB activation
in an IKK-independent manner that remains to be further
explored. RelB, which is mainly known for its activating
role in the alternative NF-jB pathway, acts as a negative
regulator of canonical NF-jB activation by the antigen
receptor [36, 54–56], most likely through the formation of
transcriptionally inactive RelA/RelB heterodimers and/or
competition at the DNA binding site [36, 57, 58]. MALT1-
dependent RelB cleavage results in its proteasomal degra-
dation, thereby lowering total levels of RelB in activated
B- and T cells [36]. Through cleavage of RelB and A20,
MALT1 thus expands the amplitude and duration of the
NF-jB response in an IKK-independent manner. Interest-
ingly, MALT1 also promotes NF-jB activation by its
autoprocessing after Arg 149. The exact consequences of
MALT1 autoprocessing remain unclear, but include an
effect on NF-jB target gene expression downstream of
nuclear NF-jB accumulation [59].
In addition to having defects in the NF-jB pathway,
MALT1-deficient cells were also reported to have an
impaired capacity to activate the JNK/AP-1 transcriptional
pathway [5]. This may be attributed at least in part to the
requirement of MALT1 for the cleavage of the deubiqui-
tinating enzyme CYLD [39], which negatively regulates
this pathway in lymphocytes through deubiquitination of
the JNK upstream kinase TAK1 [60]. Expression of a non-
cleavable form of CYLD inhibited activation of the JNK
pathway and expression of AP-1 target genes in a T-cell
line, although CYLD silencing only minimally increased
JNK activation [39], possibly because of redundancy with
other deubiquitinating enzymes. Of note, recent studies
with protease-inactive MALT1 knock-in mice have shown
that MALT1 protease activity is not required for JNK
activation [10–12]. Thus, the exact mechanism of MALT1-
and CYLD-dependent AP-1 activation and the role of JNK
in this pathway remain to be further explored.
MALT1 controls transcript stability by cleavage
of mRNA-destabilizing proteins
An entirely new aspect of MALT1’s biological function
has been revealed with the recent discovery that Regnase-1
(also known as MCPIP1 or Zc3h12a) and the Roquin-1 and -2
proteins act as MALT1 substrates [40, 41]. Regnase-1 is an
RNAse with an important function in mRNA degradation.
Regnase-1 binds to specific mRNA stem loop structures
and promotes mRNA degradation by its RNAse activity
[61] and by recruitment of the RNA remodeling helicase
UPF1 [62]. It was additionally suggested that Regnase-1
controls miRNA generation by processing of premiRNAs
[63]. MALT1-dependent cleavage of Regnase-1 lowers its
levels in activated T cells and thereby induces stabilization
of a subset of pro-inflammatory transcripts, such as IL-6,
IL-2, c-Rel and ICOS [40, 41]. As a consequence, MALT1-
dependent Regnase-1 cleavage promotes T-cell activation
[40]. Mice with a T-cell specific Regnase-1 deficiency have
exaggerated T-cell responses, which account, to a large
part, for the reported autoimmunity and systemic inflam-
mation features of Regnase-1-deficient mice [61]. The
MALT1 substrates Roquin-1 and Roquin-2 promote
mRNA degradation by binding to 3’ located stem-loop
structures in mRNA molecules known as conserved decay
elements (CDE) [64, 65]. This allows Roquin proteins to
promote mRNA deadenylation by recruitment of the cel-
lular CCR4-CAF1-NOT deadenylase complex [64].
MALT1-dependent cleavage of Roquin proteins has been
proposed to play a predominant role in the stabilization of
specific transcripts, such as IL-6, ICOS, c-Rel and IRF4,
which are also targets of Regnase-1 and collectively pro-
mote the differentiation of T effector cells of the TH17
subtype [41]. In addition to its roles in transcription and
transcript stabilization, MALT1 has been suggested to have
a role in promoting T-cell adhesion through cleavage of its
binding partner BCL10, by mechanisms that are not yet
understood [37]. Collectively, these findings suggest a
broad role for MALT1, and in particular for its protease
activity, in immune receptor-induced activation of tran-
scription, RNA stabilization and cellular adhesion (Fig. 3).
Additional, less explored roles for MALT1 and its
protease activity in lymphocytes
Beyond its established roles in activation of NF-jB and
AP-1 and transcript regulation, MALT1 most likely con-
trols other cellular activation pathways. It has for example
been proposed that MALT1 controls NF-jB2 activation
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downstream of the BAFF-receptor in specific B-cell sub-
sets, possibly via receptor-induced dissociation of MALT1
from the ubiquitin ligase TRAF3 [66] that negatively reg-
ulates BAFF-receptor-dependent survival signals [67].
Recently, MALT1 protease activity has been shown to be
required for TCR/CD28-dependent induction of glutamine
uptake and mTOR activation that controls metabolic
changes required for T-cell activation [68]. The substrate
responsible for this effect remains unknown.
MALT1 inhibition and its therapeutic potential
for lymphomas
Different compounds can be used to inhibit MALT1
in vitro and in vivo
MALT1’s enzymatic activity has stimulated efforts to
develop specific MALT1 inhibitors for research and ther-
apeutic purposes. The first MALT1 inhibitor identified was
z-VRPR-fmk, a modified tetrapeptide based on the optimal
substrate Val-Arg-Pro-Arg of the Arabidopsis thaliana
metacaspase AtmC9, conjugated to fluoromethyl ketone
(fmk) [37]. This modified peptide irreversibly blocked
MALT1 protease activity in an in vitro cleavage assay
using recombinant MALT1 in a dose-dependent manner. It
furthermore efficiently inhibited T cell activation and IL-2
secretion in Jurkat T cells and in human antigen specific
CTLs [37]. An alternative version of this inhibitor, named
z-LVSR-fmk, which is based on the LVSR substrate
sequence in the MALT1 substrate RelB [36], also inhibits
MALT1 efficiently [59]. Recently, two types of potential
small molecule MALT1 inhibitors have been identified in
high throughput screening approaches [69, 70], suggesting
that it will be feasible to develop suitable MALT1 inhibi-
tors for in vivo studies. Nagel and colleagues have
identified three phenothiazine derivatives (mepazine,
thioridazine, and promazine) as highly specific, noncom-
petitive and reversible MALT1 inhibitors [69]. A
concurrent study by Fontan and colleagues has identified
the compound MI-2 as a selective MALT1 inhibitor [70].
In contrast to phenothiazine derivatives, MI-2 engages and
irreversibly binds the active site of MALT1 [70]. Co-
crystallization of thioridazine with MALT1 has revealed
that these compounds bind the interface between the pro-
tease domain and the Ig3 domain of MALT1, an allosteric
site that is far from the active site of the enzyme [71]. Thus,
thioridazine most likely affects MALT1 activity by pre-
venting a conformational change in the protease-Ig3
interface that is essential for MALT1 activation [44, 45,
50]. Recently, two studies have reported the first generation
of MALT1 activity-based probes derived from peptide- or
phenothiazine inhibitors [72, 73]. While these are yet of
limited sensitivity, improved probes may become useful in
the future to detect MALT1 activity in pathological settings
or for measuring patient responses to MALT1 inhibitor
treatment.
The potential applications of MALT1 inhibitors in the
fields of immunomodulation and the treatment of lym-
phomas are reviewed below and illustrated in Fig. 5.
MALT1 inhibition could be a strategy to target ABC
DLBCL lymphomas
The first indication that Malt1 inhibition might be a
promising strategy to treat human diseases came from two
studies in 2009 which reported a preferential cytotoxicity
of the MALT1 inhibitor z-VRPR-fmk on a subtype of cell
lines derived from diffuse large B-cell lymphoma
(DLBCL) [74, 75]. DLBCL can be genetically classified
into molecularly distinct subtypes, including the germinal
center B cell (GCB) and the activated B cell (ABC) sub-
type. Human cases of GCB DLBCL generally show a slow
and chronic progression of the disease, whereas cases of
ABC DLBCL have a faster course, worse 5 year survival
rate and respond less well to chemotherapeutic treatment.
Growth of ABC DLBCL is driven by constitutive NF-jB
signaling that results from a variety of mechanisms [76].
These include activating mutations in the BCR-associated
CD79A/B chains, (present in roughly 23 % of ABC
DLBCL cases [77, 78]) the MALT1 activator CARMA1
(roughly 8 % of cases [77, 79]) or the TLR adaptor protein
MyD88 (37 % of cases) [80], together with inactivating
mutations in A20, a negative regulator of the NF-jB
pathway (23 % of cases) [81]. Using an RNAi screen on
ABC DLBCL cell lines, Ngo and colleagues demonstrated
that these cell lines, which have combined mutations in
MyD88 and either the CD79 or CARMA1 proteins, heavily
depend on NF-jB activation via CARMA1, BCL10 and
MALT1 for their survival and proliferation [82]. Inhibition
of MALT1 by treatment with z-VRPR-fmk, or by expres-
sion of a catalytically inactive form of MALT1, decreased
the expression of NF-jB target genes and dramatically
reduced the viability and growth of cell lines derived from
ABC DLBCL, but not from GCB DLBCL [74, 75]. Col-
lectively, these findings suggested a key role for MALT1
activity in the growth of ABC DLBCL cells.
Recently, small molecule inhibitors of MALT1 have
been shown to be effective against ABC DLBCL in
xenograft models [69, 70]. The phenothiazine derivatives
identified by Nagel et al., which act as allosteric MALT1
inhibitors, showed selective activity against ABC DLBCL
cell lines in vitro and xenotransplanted ABC DLBCL
tumors in vivo [69]. The compound MI-2, an active site
MALT1 inhibitor developed by Fontan et al., also suc-
cessfully suppressed the growth of human ABC DLBCL
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xenografts in mice without notable toxicity [70]. Thus,
MALT1 inhibitors may have potential in the treatment of
ABC DLBCL, in particular for those cases that have
oncogenic CARMA1 mutations that will render them
insensitive to compounds inhibiting BCR signaling
upstream of CARMA1, such as the Btk inhibitor Ibrutinib
[76].
Additional types of lymphomas may be targeted
by MALT1 inhibitors
Another type of lymphoma with constitutive MALT1
activity is the MALT lymphoma. A large proportion of
cases with advanced stages of this disease are characterized
by the presence of a chromosomal translocation
(t(11;18)(q21;q21) that encodes the oncogenic IAP2-
MALT1 fusion protein, composed of the N terminus of
IAP2 linked to the C terminus of MALT1. The IAP2
moiety mediates auto-oligomerization of the fusion protein
[83], rendering IAP2-MALT1 constitutively active and
able to stimulate NF-jB independently of upstream signals.
The IAP2–MALT1 fusion recruits the ubiquitin ligase
TRAF6 to promote canonical, IKK-dependent NF-jB1
activation [30]. In addition, it has constitutive protease
activity as a consequence of its monoubiquitination [51],
and can cleave natural MALT1 substrates such as A20 to
promote NF-jB1 activation [35]. Aside from activating the
canonical NF-jB pathway, the IAP2–MALT1 fusion pro-
tein specifically triggers NF-jB2 activation by the cleavage
of the Ser/Thr kinase NIK, which is detectable in MALT
lymphoma samples [84]. NIK promotes the activation of
the NF-jB2 pathway through phosphorylation and subse-
quent proteolytic maturation of the NF-jB2 precursor p100
into its transcriptionally active form p52 [85]. Normally,
the cellular activity of NIK is limited by its very short half-
life, but MALT1-dependent cleavage of NIK generates a
NIK fragment that is stable and active, thereby promoting
constitutive NF-jB2 activation to drive cellular adhesion
and protection from apoptosis of the malignant cells [84].
In addition to cleaving NIK, the IAP2-MALT1 fusion
protein has recently been shown to cleave the tumor sup-
pressor protein LIMA1, and LIMA1 cleavage products are
present in MALT lymphoma samples expressing IAP2-
MALT1 [86]. LIMA1 cleavage abolishes its tumor sup-
pressor function and generates a novel fragment with
oncogenic properties that contributes to cellular transfor-
mation [86]. The IAP2-MALT1 fusion protein thus seems
to drive cellular transformation by multiple means, sug-
gesting that inhibition of the MALT1 protease activity
could be an attractive new treatment approach for t(11;18)-
positive MALT lymphoma.
Finally, a recent study by Rahal and collegues [87]
identified a subset of MCL lines with chronic activation of
the BCR mediated CBM–NF-jB signaling pathway and
Lymphoma treatment
ABC-DLBCL
Immunomodulation
Mantle cell
lymphoma
uncontrolled lymphocyte
activation/proliferation
MALT lymphoma
Autoimmune
diseases
Inflammatory lung 
and skin diseases
Graft rejection
MALT1 inhibitor
Ref. [74,75,69,70]
Ref. [10,11,14,100]
Ref. [27,28,89,90]
Ref. [88]Ref. [84,86] 
Ref. [87]
Fig. 5 Potential fields of application of clinical MALT1 inhibitors. Possible applications include treatment of lymphomas with constitutive
MALT1 activity and immunomodulation in the context of transplantation tolerance, autoimmunity and various inflammatory disorders
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constitutive RelB cleavage, suggesting that a subset of
MCL may also be responsive to MALT1 inhibition. While
MALT1 activity has not yet been assessed in other lym-
phoma types, it seems likely that additional types of B- or
T-cell lymphomas with constitutive antigen receptor sig-
naling are sensitive to MALT1 inhibition.
Use of MALT1 inhibition for immunomodulation
MALT1 may control transplant rejection
The potential relevance of MALT1-dependent signaling
has thus far only been addressed using mice deficient for
the MALT1 upstream regulator CARMA1 and pancreatic
islet allografts [88]. Transplanted CARMA1-deficient mice
displayed a lack of T cell priming, showed very few
mononuclear cell infiltrates in the grafts and accepted fully
allogeneic islet allografts long-term. These results hold
promise that MALT1 inhibition might be beneficial in
tissue transplantation, especially for the transplantation of
less immunogenic tissues. However, since MALT1 pro-
tease inhibition is less efficient in preventing T cell
activation than complete CARMA1-deficiency, the benefits
will have to be determined experimentally. In addition, it is
of concern that CBM deficient mice as well as mice
expressing a catalytically inactive form of MALT1 display
a developmental lack of regulatory T (Treg) cells. Con-
sidering that Treg cells play a critical role in preventing
graft rejection [15], this lack of Treg cells will complicate
the interpretation of grafting experiments using these
mouse models. Whether prolonged treatment of mice with
a MALT1 inhibitor could adversely affect engraftment by
reducing Treg numbers remains to be determined.
MALT1 may be relevant for inflammatory lung
and skin disorders
CARMA1 has been shown to play an important role in the
induction of allergic asthma [89]. Immunization and chal-
lenge of wild type mice with an allergen leads to
eosinophilic airway inflammation, with production of Th2
cytokines and IgE, mucus cell hypertrophy and airway
hyperresponsiveness, whilst CARMA1-deficient mice are
protected from disease induction. A follow up study by the
same group [90] revealed that CARMA1 is also important
in recall responses when the initial priming has occurred in
the presence of CARMA1, which more closely resembles
the natural conditions of a therapeutic intervention. The
CARMA1 homologue CARMA3 (also known as CARD10)
that is expressed by airway epithelial cells is implicated in
allergic airway inflammation by mediating proinflamma-
tory cytokine production, DC maturation and migration,
antigen processing and T cell proliferation [91]. MALT1,
which acts downstream of both CARMA1 and CARMA3,
may thus bridge innate and adaptive immune responses in
the context of allergic asthma. Interestingly, mutations in
the CARMA1 homologue CARMA2 (also known as
CARD14) have been recently associated with the devel-
opment of psoriasis in human patients [27, 28]. Some of
these mutants were found to be hyperactive and to promote
expression of psoriasis-associated chemokines such as
CCL20 and IL-8 in keratinocytes [28]. Collectively, these
findings suggest that inhibition of CARMA1/2/3-dependent
signaling with a MALT1 inhibitor may have potential in
the treatment of various inflammatory disorders through
effects on immune and non-immune cells.
MALT1 may play an important role
in GPCR- and EGFR-driven pathologies
To date, little is known about the requirement of MALT1
protease activity for signaling by GPCR or the EGFR,
which both depend on MALT1 and the upstream regulator
CARMA3 (also known as CARD10) for NF-jB signaling
(see Fig. 1 and references therein). EGFR signaling does
not appear to depend on MALT1 protease activity [38],
while the requirement for MALT1 protease activity for
signaling by GPCRs has not yet been thoroughly investi-
gated. Signaling by GPCRs depending on CARMA3 and
MALT1 regulates various inflammatory processes,
including lysophosphatidic acid (LPA)-induced lung
inflammation [92], platelet-activating factor (PAF)-induced
intestinal inflammation [93] and angiotensin II-, thrombin-
and IL-8-mediated vascular inflammation [24, 94, 95].
Moreover, GPCR-signaling via CARMA3 and MALT1
may be important for LPA- or SDF-1-induced carcino-
genesis [96, 97]. Thus, whether MALT1 inhibition might
positively affect these pathological conditions merits fur-
ther investigation.
MALT1 protease-deficient mice reveal
contradictory roles for MALT1 in autoimmunity
To assess the biological relevance of the MALT1 protease
activity in vivo, several groups have recently generated
mice expressing a catalytically inactive form of the
MALT1 protease (MALT1 protease dead, MALT1-PD)
[10–13]. CARMA1- or MALT1-deficient mice are fully
protected from induction of experimental autoimmune
encephalomyelitis (EAE) by immunization with myelin
oligodendrocyte glycoprotein (MOG) [14, 98, 99], and
treatment of mice with the MALT1 inhibitor mepazine
attenuates onset and progression of the disease [100].
Interestingly, MALT1-PD mice are completely protected
from induction of EAE [10, 11], suggesting an important
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role of MALT1 in the generation and activation of
autoreactive T cells. TH17 cells play a major role in the
pathology of EAE, and both MALT1-deficient and
MALT1-PD mice show an impaired differentiation of
naı¨ve T cells into TH17 cells in vitro [11, 14]. Interest-
ingly, MOG-immunized MALT1-PD mice also have
reduced IL-17 positive T cells in the CNS [10], suggesting
that MALT1 protease-mediated signals are required for the
differentiation of autoreactive TH17 cells.
In a second autoimmune setting, using a T cell transfer
model of colitis, we demonstrated that naı¨ve T cells from
these mice less efficiently induce colon inflammation than
wild-type T-cells [10]. Unfortunately, the analysis of other
models of autoimmune diseases in MALT1-PD mice has
been severely hampered by the fact that these mice spon-
taneously develop a severe form of autoimmune disease
(Table 1). Indeed, MALT1-PD mice fail to thrive, show
neurological defects, but most intriguingly, exhibit a very
pronounced lymphadenopathy with a strong increase in B-
and T cell numbers in the lymph nodes, the presence of T
cells with an effector/memory phenotype and lymphocyte
infiltration into various organs, including the stomach,
glands, lungs, peripheral nerves and other organs [10–13].
Similar to MALT1-deficient mice, MALT1-PD mice have
a defect in regulatory T cell development, which leads to
strongly reduced regulatory T cell numbers in the thymus,
spleen and lymph nodes [10–12]. In contrast to T cells from
MALT1 knock-out mice, which are refractory to stimula-
tion, T cells from MALT1-PD mice retain some residual
activation potential, most likely though MALT1 scaffold-
dependent IKK and JNK activation [10–13]. The imbal-
ance between the residual partial T cell activation potential
on the one hand, and the lack of efficient counter-regula-
tion by regulatory T cells on the other hand, most likely
leads to the observed fatal autoimmune disease in the
otherwise immune-compromised animals. Interestingly,
some patients with MALT1 mutations also show combined
signs of immunodeficiency and autoimmune features (such
as inflammatory bowel disease) that correlate with reduced
peripheral Treg numbers [16, 17].
The compromised Treg function in MALT1-deficient or
-mutant humans and mice raises the concern that prolonged
treatment of individuals with MALT1 inhibitors may favor
the development of autoimmunity. It is important to note,
however, that the in vitro differentiation of naı¨ve T cells
from MALT1 PD mice into regulatory T cells was possible
[10, 11], indicating that this process would not be severely
hampered by a therapeutic MALT1 inhibitor. Along these
lines, mepazine did not change the percentages of regula-
tory T cells in mice that were immunized with MOG
peptide and subsequently treated daily with the inhibitor
for up to 17 days [100]. Furthermore, the presence of
mepazine did not impede the in vitro polarization of naı¨ve
mouse T cells into regulatory T cells [100]. Thus, MALT1
is strictly required for the development of natural Treg
cells, while MALT1-independent mechanisms seem to be
important for the generation of inducible Treg cells. Fur-
ther experiments are however required to assess potential
adverse effects of MALT1 inhibition on Treg cell devel-
opment and function.
Conclusions and perspectives
MALT1 has an essential role in the immune response and
the growth of lymphoma cells with constitutive MALT1
activity. Studies with MALT1-deficient mice and MALT1
inhibitors have suggested that MALT1 could be a rational
drug target for immunomodulation and lymphoma treat-
ment. The recent development of mice expressing
Table 1 Features of MALT1 protease-dead mice, summarizing
defects in lymphocyte development and leukocyte activation and
responses to disease models
Observed features References
Lymphocyte development
Reduced number of regulatory T cells [10–12]
Impaired development of B1 and MZ B cells [10–13]
Increased CD3 expression on DN4 thymocytes [10]
Leukocyte properties
Impaired T cell activation [10, 11,
13]
Impaired NK cell activation [10]
Impaired DC activation [10, 13]
Impaired B cell response to immunization [10, 11,
13]
Histological findings/pathology
Failure to thrive, weight loss [10–13]
Neurological disorder and paralysis [11–13]
Loss of Purkinje cells in cerebellum, elevated T cell
numbers in the brain
[12]
Increased percentages of effector/memory T cells [10–12]
Increased percentages of CD4? T cells expressing IFNc
and IL-4
[10, 11]
Elevated serum concentrations of IFNc and TNFa [12]
Lymphadenopathy with strong increase in T and B cell
numbers
[10–12]
Lymphoid cell infiltration in glandular stomach, glands,
lungs, peripheral nerves and other organs
[10–13]
Increased serum levels of IgG1 and IgE [10, 11]
Autoantibodies recognizing parietal cells of the stomach [10]
Response in experimental disease models
Protection from experimental autoimmune
encephalomyelitis (EAE)
[10, 11]
Lower penetrance of T cell transfer colitis [10]
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catalytically inactive MALT1 confirms not only its essen-
tial role in the immune response, but also highlights the
fact that MALT1 activity is required for the development
of natural Treg cells that prevent autoimmunity. Impor-
tantly, MALT1 inhibition does not prevent the
differentiation of naı¨ve T cells into Treg cells. Additional
studies are thus required to assess whether the long-term
use of MALT1 inhibitors may affect Treg functions in the
adult, which is of obvious concern for immunomodulation,
but maybe less evident for the treatment of lymphomas.
An important perspective for future research on MALT1
will be to further explore its molecular function and to
identify the full spectrum of its substrates, which may open
additional windows for therapeutic applications. Another
major challenge will be to better understand MALT1’s
physiological function in non-immune cells, and its rele-
vance not only for immune but also for non-immune
pathologies.
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